AI Article Synopsis
- The review highlights the clinical use of FDG PET in neurology, emphasizing its role in diagnosing and managing conditions like dementia, epilepsy, and neuro-oncology.
- Many insurance companies cover PET scans for these indications, reflecting their importance in patient care.
- By offering insights into brain function that other tests can't provide, PET scans help doctors make better, more cost-effective treatment decisions that benefit patients and the healthcare system.
Article Abstract
This short review focuses on practical, present day, clinical application of FDG PET, a technology available to practicing neurologists for managing their patients. Indications in the disease states of dementia, neuro-oncology, epilepsy, parkinsonism, and other less common settings are reviewed. Many third-party payers currently make reimbursements based on these indications. By measuring an aspect of brain function, PET provides information that often is unobtainable from other sources, thus facilitating more rationale and cost-effective management, which can only benefit the patient, the referring physician, and the health care system as a whole.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ncl.2008.09.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The potential role of machine learning and deep learning in differential diagnosis of Alzheimer's disease and FTD using imaging biomarkers: A review.
Neuroradiol J
January 2025
Department of Medical Physics, Faculty of Medicine, Mashhad University of Medical Sciences, Iran.
Introduction: The prevalence of neurodegenerative diseases has significantly increased, necessitating a deeper understanding of their symptoms, diagnostic processes, and prevention strategies. Frontotemporal dementia (FTD) and Alzheimer's disease (AD) are two prominent neurodegenerative conditions that present diagnostic challenges due to overlapping symptoms. To address these challenges, experts utilize a range of imaging techniques, including magnetic resonance imaging (MRI), diffusion tensor imaging (DTI), functional MRI (fMRI), positron emission tomography (PET), and single-photon emission computed tomography (SPECT).
View Article and Find Full Text PDFReproducibility and repeatability of 18F-(2S, 4R)-4-fluoroglutamine PET imaging in preclinical oncology models.
PLoS One
January 2025
Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, United States of America.
Introduction: Measurement of repeatability and reproducibility (R&R) is necessary to realize the full potential of positron emission tomography (PET). Several studies have evaluated the reproducibility of PET using 18F-FDG, the most common PET tracer used in oncology, but similar studies using other PET tracers are scarce. Even fewer assess agreement and R&R with statistical methods designed explicitly for the task.
View Article and Find Full Text PDFValidation of the 2022 ACR/EULAR classification criteria for giant cell arteritis in Koran patients with giant cell arteritis.
Mod Rheumatol
January 2025
Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Objectives: We applied the 2022 American College of Rheumatology (ACR)/European Alliance of Association for Rheumatology (EULAR) criteria to Korean patients previously diagnosed with giant cell arteritis (GCA) according to the 1990 ACR criteria and validated its clinical efficiency.
Methods: Nine patients with GCA were included in this study. The proportion of patients meeting each item of the 1990 ACR criteria and the 2022 ACR/EULAR criteria were assessed.
Screening for cardiac sarcoidosis: diagnostic approach and long-term follow-up in a tertiary centre.
Neth Heart J
January 2025
Department of Cardiology, Thorax Centre, Cardiovascular Institute, Erasmus Medical Centre, Rotterdam, The Netherlands.
Background: Cardiac sarcoidosis (CS) is associated with poor prognosis, making early diagnosis and treatment important. This study evaluated the results of a diagnostic approach in patients with known sarcoidosis and suspected cardiac involvement in a tertiary centre and their long-term outcomes.
Methods: We included 180 patients with sarcoidosis and a clinical suspicion of CS.
Biomarkers.
Alzheimers Dement
December 2024
The Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Israel.
Background: Amyloid beta (Aβ) deposition marks an early stage in the progression of Alzheimer's disease (AD), detectable in-vivo years before symptoms emerge and targeted by recently FDA-approved drugs. This has propelled advancements in understanding, measuring, and treating AD, paving the way for disease prevention in those at risk. However, the psychological impact of disclosing Aβ status to cognitively unimpaired individuals remains underexplored.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!